CD20 Monoclonal Antibody (2H7), eFluor™ 450, eBioscience™, Invitrogen™

Description

• Description: The 2H7 monoclonal antibody reacts with human CD20, a 33-36 kDa transmembrane protein
• CD20 is expressed by developing B cells as well as mature B cells but not plasma cells
• CD20 has been detected at low levels on a small subset of mature T cells
• It is suggested that CD20 plays a role in B-cell activation
• Applications Reported: This 2H7 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This 2H7 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.5 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• eFluor™ 450 is an alternative to Pacific Blue™
• eFluor™ 450 emits at 445 nm and is excited with the Violet laser (405 nm)
• Please make sure that your instrument is capable of detecting this fluorochome
• Excitation: 405 nm; Emission: 445 nm; Laser: Violet Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation
• CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells
• CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation
• CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation
• After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface
• CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment
• Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency.